MX356873B - Uso farmacéutico de una esfingomielinasa ácida (asm) con aumento escalonada de la dosis para tratar la deficiencia de esfingomielinasa ácida. - Google Patents

Uso farmacéutico de una esfingomielinasa ácida (asm) con aumento escalonada de la dosis para tratar la deficiencia de esfingomielinasa ácida.

Info

Publication number
MX356873B
MX356873B MX2012002449A MX2012002449A MX356873B MX 356873 B MX356873 B MX 356873B MX 2012002449 A MX2012002449 A MX 2012002449A MX 2012002449 A MX2012002449 A MX 2012002449A MX 356873 B MX356873 B MX 356873B
Authority
MX
Mexico
Prior art keywords
acid sphingomyelinase
replacement therapy
dose escalation
enzyme replacement
treating acid
Prior art date
Application number
MX2012002449A
Other languages
English (en)
Other versions
MX2012002449A (es
Inventor
H Schuchman Edward
J Desnick Robert
f cox Gerald
P Andrews Laura
M Murray James
Original Assignee
Sinai School Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43625265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX356873(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sinai School Medicine filed Critical Sinai School Medicine
Publication of MX2012002449A publication Critical patent/MX2012002449A/es
Publication of MX356873B publication Critical patent/MX356873B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Dermatology (AREA)

Abstract

La presente invención se refiere a la terapia de reemplazo de enzimas con aumento escalonado de la dosis que utiliza la esfingomielinasa ácida (ASM) para el tratamiento de sujetos humanos con deficiencia de esfingomielinasa ácida (ASMD) y, en particular, pacientes con manifestaciones no neurológicas de la enfermedad de Niemann Pick (NPD) y, en determinadas aplicaciones, con NPD tipo B.
MX2012002449A 2009-08-28 2010-08-28 Uso farmacéutico de una esfingomielinasa ácida (asm) con aumento escalonada de la dosis para tratar la deficiencia de esfingomielinasa ácida. MX356873B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23811309P 2009-08-28 2009-08-28
PCT/US2010/047057 WO2011025996A2 (en) 2009-08-28 2010-08-28 Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency

Publications (2)

Publication Number Publication Date
MX2012002449A MX2012002449A (es) 2012-03-14
MX356873B true MX356873B (es) 2018-06-18

Family

ID=43625265

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002449A MX356873B (es) 2009-08-28 2010-08-28 Uso farmacéutico de una esfingomielinasa ácida (asm) con aumento escalonada de la dosis para tratar la deficiencia de esfingomielinasa ácida.

Country Status (26)

Country Link
US (9) US8349319B2 (es)
EP (3) EP3482767B1 (es)
JP (7) JP5955219B2 (es)
KR (5) KR20200034828A (es)
CN (3) CN105999238A (es)
AU (5) AU2010286550B2 (es)
BR (1) BR112012004377A2 (es)
CA (1) CA2773133A1 (es)
CL (1) CL2012000495A1 (es)
CY (1) CY1122128T1 (es)
DK (2) DK3482767T3 (es)
ES (2) ES2902229T3 (es)
FR (1) FR22C1062I2 (es)
HR (2) HRP20211992T1 (es)
HU (3) HUE046598T2 (es)
IL (3) IL300625A (es)
LT (2) LT2470199T (es)
MX (1) MX356873B (es)
NL (1) NL301211I2 (es)
PL (2) PL3482767T3 (es)
PT (2) PT3482767T (es)
RU (3) RU2731616C2 (es)
SI (2) SI2470199T1 (es)
TR (1) TR201911293T4 (es)
WO (1) WO2011025996A2 (es)
ZA (2) ZA201201435B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889127B2 (en) 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
US20080228056A1 (en) 2007-03-13 2008-09-18 Michael Blomquist Basal rate testing using frequent blood glucose input
US7751907B2 (en) 2007-05-24 2010-07-06 Smiths Medical Asd, Inc. Expert system for insulin pump therapy
US8221345B2 (en) 2007-05-30 2012-07-17 Smiths Medical Asd, Inc. Insulin pump based expert system
ES2905616T3 (es) 2007-06-06 2022-04-11 Genzyme Corp Terapia génica para enfermedades de almacenamiento lisosómico
PT3482767T (pt) * 2009-08-28 2021-12-29 Icahn School Med Mount Sinai Terapia de substituição enzimática com escaladas de dose para tratamento de deficência da esfingomielinase ácida
US8882701B2 (en) * 2009-12-04 2014-11-11 Smiths Medical Asd, Inc. Advanced step therapy delivery for an ambulatory infusion pump and system
WO2011146143A2 (en) 2010-05-21 2011-11-24 Ohmx Corporation Detection of cancer by assaying psa enzymatic activity
CN107080747B (zh) 2011-03-18 2021-02-26 建新公司 葡萄糖基神经酰胺合酶抑制剂
DK2753346T3 (da) 2011-09-07 2020-05-25 Sinai School Medicine Ceramidase og celledifferentiering
MX359328B (es) * 2011-11-15 2018-09-25 Centogene Ag Metodo para el diagnostico de enfermedad de niemann-pick.
EP3679923B1 (en) 2012-06-01 2021-08-04 Icahn School of Medicine at Mount Sinai Ceramide levels in the treatment and prevention of infections
JOP20130273B1 (ar) 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
JP6832158B2 (ja) * 2013-03-14 2021-02-24 アイカーン スクール オブ メディシン アット マウント サイナイ 治療用酸性セラミダーゼ組成物ならびにそれを作製および使用する方法
JO3713B1 (ar) 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
ES2731920T3 (es) * 2013-05-14 2019-11-19 Centogene Ag Método para el diagnóstico de la enfermedad de Niemann-Pick
HUE047863T2 (hu) * 2013-06-07 2020-05-28 Genzyme Corp Marker savas szfingomielináz rendellenességekhez és alkalmazásai
JP6984854B2 (ja) * 2015-10-08 2021-12-22 国立大学法人千葉大学 ニーマン・ピック病ｃ型を予防または治療するための医薬組成物
US10569016B2 (en) 2015-12-29 2020-02-25 Tandem Diabetes Care, Inc. System and method for switching between closed loop and open loop control of an ambulatory infusion pump
EP3672622B1 (en) * 2017-08-24 2023-11-08 Genzyme Corporation Recombinant human acid sphingomyelinase for use in treating abnormal bone conditions in acid sphingomyelinase deficiency patients
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
UY38238A (es) 2018-05-25 2019-12-31 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
US11857512B2 (en) 2020-07-24 2024-01-02 Genzyme Corporation Pharmaceutical compositions comprising venglustat

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039388A (en) 1976-06-04 1977-08-02 The United States Of America As Represented By The Government Diagnostic test for Niemann-Pick disease
US4082781A (en) 1976-06-04 1978-04-04 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of 2-alkanoylamino-4-nitrophenyl phosphorylcholine-hydroxide
IL74761A0 (en) 1984-04-13 1985-06-30 Hughes Howard Med Inst Human phenylalanine hydroxylase cdna clones,their production and their use in diagnosing classical phenylketonuria
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4863195A (en) * 1987-10-02 1989-09-05 Capozzola Carl A Identification tag
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5773278A (en) * 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5612487A (en) 1991-08-26 1997-03-18 Edible Vaccines, Inc. Anti-viral vaccines expressed in plants
US5484719A (en) 1991-08-26 1996-01-16 Edible Vaccines, Inc. Vaccines produced and administered through edible plants
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5716614A (en) 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
US5929304A (en) 1995-09-14 1999-07-27 Croptech Development Corporation Production of lysosomal enzymes in plant-based expression systems
JP2820106B2 (ja) 1996-02-29 1998-11-05 日本電気株式会社 トラヒックシェーパ装置
IL155588A0 (en) 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
US20050032211A1 (en) 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
CN100410268C (zh) 1998-12-23 2008-08-13 博伊斯汤普生植物研究所 免疫原性的乙型肝炎表面抗原在转基因植物中的表达
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
US6770799B2 (en) 2000-03-17 2004-08-03 Thompson Boyce Plant Res Expression of recombinant human acetylcholinesterase in transgenic plants
WO2001097829A2 (en) * 2000-06-19 2001-12-27 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
AU2001286636A1 (en) 2000-08-25 2002-03-13 Lysometrix Corporation Method for assaying the activity of lysosomal enzymes
US7723296B2 (en) * 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7001994B2 (en) * 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
EP1974752B1 (en) 2001-04-30 2012-09-26 BioMarin Pharmaceutical Inc. Subcellular targeting of therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
IES20011101A2 (en) * 2001-12-21 2003-06-25 Japkinstill Services Ltd A Bi-directional Messaging System
AU2003224880A1 (en) * 2002-04-05 2003-10-27 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy
US7585518B2 (en) 2002-11-19 2009-09-08 Kimberly-Clark Worldwide, Inc. Products and methods for maintaining or increasing ceramide levels in skin
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
CA2528427A1 (en) 2003-06-12 2004-12-23 Genzyme Corporation Modified human acid sphingomyelinase having increased activity, and methods for making the same
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
CN101214249A (zh) 2003-11-25 2008-07-09 纽约大学西奈山医学院 尼曼-皮克病的基于陪伴分子的治疗
ATE468390T1 (de) 2004-10-13 2010-06-15 Protalix Ltd System und verfahren zur produktion von antikörpern in der pflanzenzellkultur
US7615224B2 (en) 2004-12-02 2009-11-10 Women's And Children's Hospital Multiplex-bead complex for determination of lysosomal storage disorders
KR20080082984A (ko) 2005-12-15 2008-09-12 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 혈장 및 조직의 스핑고마이엘린 및 포스파티딜콜린의효소적 측정 방법
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
WO2007091250A2 (en) 2006-02-06 2007-08-16 The Medical Research And Infrastructure Fund Of The Tel-Aviv Sourasky Medical Center Enzyme replacement therapy for treating lysosomal storage diseases
CA2641359C (en) 2006-02-09 2022-10-04 Genzyme Corporation Slow intraventricular delivery
CA2642054C (en) 2006-02-13 2017-11-21 Fraunhofer Usa, Inc. Influenza antigens, vaccine compositions, and related methods
JP5302189B2 (ja) 2007-04-27 2013-10-02 長瀬産業株式会社 スフィンゴミエリナーゼ
US20110237538A1 (en) 2008-08-06 2011-09-29 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
JP5658167B2 (ja) 2008-12-16 2015-01-21 ジェンザイム・コーポレーション オリゴ糖−タンパク複合体
PT3482767T (pt) * 2009-08-28 2021-12-29 Icahn School Med Mount Sinai Terapia de substituição enzimática com escaladas de dose para tratamento de deficência da esfingomielinase ácida
JP6175431B2 (ja) * 2011-06-20 2017-08-02 アイカーン スクール オブ メディシン アット マウント サイナイ ムコ多糖症およびその他のリソソーム障害に対する抗ｔｎｆ療法

Also Published As

Publication number Publication date
AU2018204156A1 (en) 2018-06-28
JP7395693B2 (ja) 2023-12-11
US20190151419A1 (en) 2019-05-23
RU2015145255A3 (es) 2019-08-12
MX2012002449A (es) 2012-03-14
US8658162B2 (en) 2014-02-25
US8349319B2 (en) 2013-01-08
PL2470199T3 (pl) 2019-11-29
JP2016153408A (ja) 2016-08-25
KR20210107153A (ko) 2021-08-31
JP2023012499A (ja) 2023-01-25
ZA201601362B (en) 2017-05-31
US9114139B2 (en) 2015-08-25
KR20220104271A (ko) 2022-07-26
US20210077593A1 (en) 2021-03-18
JP2024026214A (ja) 2024-02-28
ES2738859T3 (es) 2020-01-27
EP2470199A4 (en) 2013-03-27
EP3482767B1 (en) 2021-10-06
JP2020090513A (ja) 2020-06-11
CN102596232A (zh) 2012-07-18
BR112012004377A2 (pt) 2017-12-12
JP2013502933A (ja) 2013-01-31
US10188705B2 (en) 2019-01-29
CY1122128T1 (el) 2020-11-25
EP2470199A2 (en) 2012-07-04
JP6952810B2 (ja) 2021-10-20
FR22C1062I2 (fr) 2023-12-29
PT3482767T (pt) 2021-12-29
AU2010286550A1 (en) 2012-03-15
NL301211I2 (nl) 2023-02-02
JP6251307B2 (ja) 2017-12-20
PL3482767T3 (pl) 2022-02-14
US20160120957A1 (en) 2016-05-05
SI2470199T1 (sl) 2019-11-29
US8709408B2 (en) 2014-04-29
CL2012000495A1 (es) 2014-02-07
US9655954B2 (en) 2017-05-23
AU2010286550B2 (en) 2016-05-19
EP3482767A1 (en) 2019-05-15
SI3482767T1 (sl) 2022-03-31
IL266915A (en) 2019-07-31
DK3482767T3 (da) 2021-12-20
FR22C1062I1 (fr) 2023-02-03
WO2011025996A2 (en) 2011-03-03
US20130078230A1 (en) 2013-03-28
EP3998078A1 (en) 2022-05-18
JP2018076322A (ja) 2018-05-17
JP5955219B2 (ja) 2016-07-20
ES2902229T3 (es) 2022-03-25
IL266915B2 (en) 2023-07-01
AU2016216625A1 (en) 2016-09-15
US20130078231A1 (en) 2013-03-28
PT2470199T (pt) 2019-08-07
KR102608546B1 (ko) 2023-12-04
US20180055916A1 (en) 2018-03-01
HRP20211992T1 (hr) 2022-04-01
IL218324B (en) 2019-05-30
US20220305091A1 (en) 2022-09-29
KR20120081077A (ko) 2012-07-18
WO2011025996A3 (en) 2012-03-15
LT3482767T (lt) 2022-01-10
US20110052559A1 (en) 2011-03-03
IL218324A0 (en) 2012-04-30
AU2024201085A1 (en) 2024-03-07
KR102608551B1 (ko) 2023-12-04
KR102094253B1 (ko) 2020-03-31
HUE046598T2 (hu) 2020-03-30
LT2470199T (lt) 2019-10-10
HUE057440T2 (hu) 2022-05-28
HRP20191385T1 (hr) 2019-11-01
AU2020256322A1 (en) 2020-11-12
AU2020256322B2 (en) 2024-02-29
US20140335070A1 (en) 2014-11-13
RU2020128994A (ru) 2022-03-02
EP2470199B1 (en) 2019-05-22
RU2015145255A (ru) 2019-01-11
CA2773133A1 (en) 2011-03-03
RU2731616C2 (ru) 2020-09-07
WO2011025996A9 (en) 2011-08-25
DK2470199T3 (da) 2019-08-05
ZA201201435B (en) 2020-05-27
NL301211I1 (nl) 2022-12-28
AU2016216625B2 (en) 2018-07-05
TR201911293T4 (tr) 2019-08-21
CN105999238A (zh) 2016-10-12
CN106047835A (zh) 2016-10-26
AU2018204156B2 (en) 2020-07-16
KR20230164773A (ko) 2023-12-04
JP2022003065A (ja) 2022-01-11
RU2569744C2 (ru) 2015-11-27
KR20200034828A (ko) 2020-03-31
IL300625A (en) 2023-04-01
HUS2200050I1 (hu) 2022-12-28
IL266915B1 (en) 2023-03-01
JP7167281B2 (ja) 2022-11-08
RU2012111823A (ru) 2013-10-10

Similar Documents

Publication Publication Date Title
MX2012002449A (es) Terapia de reemplazo de enzimas con aumento escalonado de la dosis para tratar la deficiencia de esfingomielinasa acida.
MX2011007397A (es) Inhibidores de dpp-iv para el tratamiento de la diabetes en pacientes pediatricos.
MX2019002669A (es) Composicion farmaceutica para usarse en el tratamiento de la malnutricion en un sujeto que exhibe un trastorno de espectro de autismo (asd).
EA201490004A1 (ru) Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
MX2019005130A (es) Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmaceuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabeticos tipificados geneticamente.
EP2494059A4 (en) USE OF METHYSULFONYLMETHANE (MSM) FOR MODULATION OF MICROBIAL ACTIVITY
MX340515B (es) Terapia antidiabética vasoprotectora y cardioprotectora.
TN2011000176A1 (en) Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
EP3447491A3 (en) Diagnosis and treatments relating to th2 inhibition
MX350046B (es) Tratamientos para trastornos gastrointestinales.
MX2012014521A (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion.
BRPI1010861A8 (pt) métodos para tratamento de dor, inflamação ou osteoartrite, pacote e formulação farmacêutica
CO6430497A2 (es) Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento
MX2010000938A (es) Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin-1-carboxílico para el tratamiento del trastorno por estrés postraumático.
EP2566502A4 (en) METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION
MX371198B (es) Terapia antidiabetica vasoprotectora y cardioprotectora.
CY1119845T1 (el) Ενα γαλακτοκομικο προϊον μειωμενης χοληστερολης για χρηση στην θεραπευτικη αντιμετωπιση και/ή προληψη μιας ασθενειας του ηπατος
UA41106U (ru) Способ лечения гипостатической пневмонии у больных с хронической сердечной недостаточностью
UA44534U (ru) Способ лечения синдрома эйзенменгера
UA29611U (ru) Способ имплантации электродов для регистрации биоэлектрической активности базальных височных отделов головного мозга
UA106357C2 (ru) Лечение диабета у пациентов, у которых наблюдается недостаточный гликемический контроль, несмотря на лечение пероральным или непероральным противодиабетическим лекарственным средством

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: VERTEX PHARMACEUTICALS INCORPORATED.*

FG Grant or registration